Alterity Therapeutics Limited Short Interest Update
ATHE Stock | USD 4.08 0.11 2.63% |
About 55% of Alterity Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding Alterity Therapeutics suggests that many traders are impartial. The current market sentiment, together with Alterity Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Alterity Therapeutics stock news signals to limit their universe of possible portfolio assets.
Alterity |
Alterity Therapeutics Limited was the target of a significant decrease in short interest in April. As of April 30th, there was short interest totalling 15,000 shares, a decrease of 35.3 percent from the April 15th total of 23,200 shares. Currently, 0.4 percent of the companys stock are sold short. Based on an average
Read at thelincolnianonline.com
![]() |
Alterity Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Alterity Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Alterity Therapeutics Fundamental Analysis
We analyze Alterity Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alterity Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alterity Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Ratio
Current Ratio Comparative Analysis
Alterity Therapeutics is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Alterity Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Alterity Therapeutics stock to make a market-neutral strategy. Peer analysis of Alterity Therapeutics could also be used in its relative valuation, which is a method of valuing Alterity Therapeutics by comparing valuation metrics with similar companies.
Peers
Alterity Therapeutics Related Equities
NBY | NovaBay Pharmaceuticals | 4.76 | ||||
PMVP | Pmv Pharmaceuticals | 1.42 | ||||
SRZN | Surrozen | 1.25 | ||||
ANTX | AN2 Therapeutics | 0.88 | ||||
ANEB | Anebulo Pharmaceuticals | 0.79 | ||||
ADIL | Adial Pharmaceuticals | 2.53 | ||||
QNRX | Quoin Pharmaceuticals | 3.13 | ||||
ARTL | Artelo Biosciences | 3.33 | ||||
TARA | Protara Therapeutics | 4.03 | ||||
ATXI | Avenue Therapeutics | 4.41 | ||||
HCWB | HCW Biologics | 5.13 | ||||
RVPH | Reviva Pharmaceuticals | 7.01 | ||||
MNPR | Monopar Therapeutics | 10.58 | ||||
RNAZ | Transcode Therapeutics | 15.99 |
Complementary Tools for Alterity Stock analysis
When running Alterity Therapeutics' price analysis, check to measure Alterity Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alterity Therapeutics is operating at the current time. Most of Alterity Therapeutics' value examination focuses on studying past and present price action to predict the probability of Alterity Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alterity Therapeutics' price. Additionally, you may evaluate how the addition of Alterity Therapeutics to your portfolios can decrease your overall portfolio volatility.
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Commodity Directory Find actively traded commodities issued by global exchanges |